ProCE Banner Activity

Phase II Trial: Olaparib + Abiraterone vs Placebo + Abiraterone for Metastatic CRPC Following Chemotherapy

Slideset Download
Conference Coverage
Combination of a PARP inhibitor plus ADT increases radiologic PFS in patients with docetaxel-treated mCRPC.

Released: June 03, 2018

Expiration: June 02, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen